Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease.

ABSTRACT: Marraset al. report a low number needed to treat and high number needed to harm supporting addition of amikacin liposome inhalation suspension to guideline-based treatments in patients with treatment-refractory Mycobacterium avium complex lung disease https://bit.ly/3tPFW7D.

SUBMITTER: Marras TK 

PROVIDER: S-EPMC9271752 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature